The positive outcome of the Phase 2a trial for bexotegrast, including potential fibrosis reversal, improved lung function, and a favorable safety profile, directly impacts Pliant Therapeutics' market perception and investor confidence, leading to a short-term positive impact on PLRX stock price. The increase in stock price following the announcement confirms market optimism regarding the trial results and the potential commercial success of bexotegrast.